DIABETIK RETINOPATIYADA TERAPEVTIK MAQSAD SIFATIDA NEYROPROTEKTSIYA
##article.subject##:
Diabetik retinopatiya. Neyrodejeneratsiya. Neyroprotektsiya. Diyabetik retinopatiyani davolash. Neyrovaskulyar birikma##article.abstract##
Diyabetik retinopatiya (DR) to'r pardaning mikrosirkulyator kasalligi hisoblanadi. Shu bilan birga, to'r pardaning neyrodegeneratsiyasi DR patogenezidagi dastlabki hodisa bo'lib, u DRda yuzaga keladigan mikrosirkulyator buzilishlar rivojlanishidan oldin, shuningdek ularda qatnashishi mumkin degan yangi ma'lumotlar paydo bo'lmoqda. Shu sababli, neyrodegeneratsiyaga olib keladigan asosiy mexanizmlarni o'rganish DRning dastlabki bosqichlarida yangi terapevtik maqsadlarni aniqlash uchun juda muhimdir. Glyutamat darajasining ko'tarilishi, oksidlanish stressi, renin-angiotenzin tizimining haddan tashqari ekspressi va glykirlanish natijasida paydo bo'lgan yakuniy maxsulotlar retseptorlari faollashishi diabet bilan bog'liq to'r pardaning neyrodegeneratsiyasida muhim rol o'ynaydi. Shuningdek, retinal neyronlarning hayotiyligini aniqlashda neyrotoksik va neyroprotektiv omillar o'rtasidagi muvozanat juda muhimdir. Ushbu sharxda biz fiziologik sharoitda to'r pardada sintez qilingan neyrotrofik omillarga e'tibor qaratamiz va DRni davolashning xozirgi neyroprotektiv strategiyalari va kelajakdagi yo'nalishlarini muhokama qilamiz.
Библиографические ссылки
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–36.
Javitt JC. Cost savings associated with detection and treatment of diabetic eye disease. PharmacoEconomics. 1995;8
Mattews D.R., Stratton I.M., Aldington S.J. et al. UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related. Arch. Opthalmol. 2004; 12 (11): 1631–40.
Астахов Ю.С., А.Б. Лисочкина, Ф.Е. Шадричев. Современные направления медикаментозного лечения непролиферативной диабетической ретинопатии // Клин. Офтальмология: РМЖ. - 2003. - Т.4, №3. - С. 96-101.
Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51:1574–80.
Lieth E, Gardner TW, Barber AJ, Antonetti DA, Penn State Retina Research Group. Retinal neurodegeneration: early pathology in diabetes. Clin Exp Ophthalmol. 2000;28:3–8.
Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res. 1998;17:59–76.
Bearse jr MA, Adams AJ, Han Y, et al. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res. 2006;25:425–48
Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol. 2006;38:752–65.
Shen X, Xie B, Cheng Y, et al. Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocul Immunol Inflamm. 2011;19:246–54.
Hernández C, Simó R. Strategies for blocking angiogenesis in diabetic retinopathy: fom basic science to clinical practice. Expert Opin Invest Drugs. 2007;16:1209–26.
Castillo M., Bellot J.L., Garcia-Cabanes С. et al. Effects of hypoxia on retinal pigmented epithelium cells: protection by antioxidants. Opthal. Res. 2002; 6: 338–42. 8. Smith S.C. Focus on diabetes. Insight. 2006; 31 (1): 21–2.
Cervia D, Casini G, Bagnoli P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol Cell Endocrinol. 2008;286:112–22.
Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782–92.
Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27:530–43.
SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res. 2005;24:87–138.
Villarroel M, Ciudin A, Hernández C, Simó R. Neurodegeneration: an early event of diabetic retinopathy. World J Diabetes. 2010;1:57–64
Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. 2007; 298:902–16.
Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia. 2001;44:791–804.
Joussen AM, Joeres S. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol. 2007;39:69–87.
Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops. Proc Natl Acad Sci USA. 2008;106:13469–74
